Article Text

Download PDFPDF

226 Comorbidity in systemic lupus erythematosus
  1. Bugra Egeli1,
  2. Asli Ece Soykut1 and
  3. Serdal Ugurlu2
  1. 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty
  2. 2Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa


Background In Systemic Lupus Erythematosus (SLE), cardiovascular mortality is important. In our previous study, we observed atherosclerotic plaque formation in carotid and/or femoral artery in SLE patients.1 The aim of this study was to assess the comorbidity of the patients diagnosed with SLE over 10 years.

Methods The sample group is a subset of 2009 study. In 2009, the patients who already had myocardial infarction or cancer diagnosis were excluded. The patients were interviewed with polar questions of whether they were diagnosed with acute myocardial infarction (AMI), cerebrovascular events, cancer, diabetes, and hypertension.

Results We studied 65 patients (56F, 9 M; mean age: 53±8.76) with SLE diagnosis.

In 2009, out of 94 SLE patients we included in the study, 2 (2.13%) of the patients were diagnosed with diabetes, and 33 (35.11%) with hypertension. However, in 2018, out of the 65 patients we reached, 8 (12.31%) with diabetes, and 37 (56.92%) with hypertension. The increase in diabetes and hypertension was found significant. (p=0.009 and 0.006) The table 1 shows the percentages of newly occurred cancer, angina pectoris, and AMI/Stroke events.

Conclusions In 10 year follow-up, the significant increase in hypertension and diabetes can show us a sign of atherosclerotic plaque formation. However, the increased hypertension and diabetes ratio can still be due to increased age.

Abstract 226 Table 1

Prognostic factors of SLE patients in 2009 and 2018

Funding Source(s): None


  1. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford). 2009 August;48(8):911–5.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.